Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 4/20 | 0.53 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.53 |
| ▸ | GRIK3 | Q13003 | 4/20 | 0.53 |
| ▸ | GRIK4 | Q16099 | 4/20 | 0.53 |
| ▸ | GRIK5 | Q16478 | 4/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.53 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.53 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GRM6 | O15303 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8621697 | 0.89 | GRIK1 (0.38) | GRIK1GRIK2GRIK3GRIK4GRIK5 | |
| SCHEMBL3683015 | 0.87 | GRIA1 (0.58) | GRIK1GRIK2GRIK3GRIK4GRIK5 | |
| SCHEMBL8624233 | 0.84 | GRIA1 (0.38) | GRIK1GRIK2GRIK3GRIK4GRIK5 | |
| SCHEMBL8621605 | 0.84 | PARP1 (0.42) | GRIK1GRIK2GRIK3GRIK4GRIK5 | |
| SCHEMBL8617971 | 0.84 | SIRT2 (0.40) | GRIK1GRIK2GRIK3GRIK4GRIK5 | |
| SCHEMBL8623608 | 0.84 | GRIK1 (0.38) | GRIK1GRIK2GRIK3GRIK4GRIK5 | |
| SCHEMBL8617950 | 0.83 | KDM4E (0.52) | GRIK1GRIK2GRIK3GRIK4GRIK5 | |
| SCHEMBL8624317 | 0.82 | KDM4E (0.51) | GRIK1GRIK2GRIK3GRIK4GRIK5 | |
| SCHEMBL8624851 | 0.82 | KMT2A (0.33) | GRIK1GRIK2GRIK3GRIK4GRIK5 | |
| SCHEMBL8622998 | 0.81 | KDM4E (0.49) | GRIK1GRIK2GRIK3GRIK4GRIK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8603980-B2 | Glutamate receptor antagonists and methods of use | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-12-10 | — | — | US | disclosed |
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| US-5710138-A | Benzo f!quinoxalinedione derivatives, their production and use in pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-01-20 | — | — | US | disclosed |
| EP-0696289-B1 | BENZO[F]QUINOXALINDIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN DRUGS | SCHERING AG (DE) | 1997-03-12 | — | — | EP | disclosed |
| EP-0696289-A1 | BENZO F]QUINOXALINDIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN DRUGS | SCHERING AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994025470-A1 | BENZO[F]QUINOXALINDIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | GRM5, GRM1, GRM3 | GRIK1 14/4885GRIK2 16/4885GRIK3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.